Section Arrow
Quote
BPMC.NASDAQ
- Blueprint Medicines Corp
Quotes are at least 15-min delayed:2024/05/16 06:51 EDT
Last
 106.79
+1.33 (+1.26%)
Day High 
108.75 
Prev. Close
105.46 
1-M High
111.02 
Volume 
758.09K 
Bid
98.33
Ask
170.86
Day Low
106.09 
Open
107.88 
1-M Low
84.33 
Market Cap 
6.60B 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 106.12 
20-SMA 98.43 
50-SMA 93.52 
52-W High 111.02 
52-W Low 43.89 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.82/-1.62
Enterprise Value
6.89B
Balance Sheet
Book Value Per Share
4.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
249.38M
Operating Revenue Per Share
3.45
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed：2024/05/16 06:51 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.